BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26558352)

  • 1. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
    Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB
    Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
    Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
    Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
    Bo MD; Del Principe MI; Pozzo F; Ragusa D; Bulian P; Rossi D; Capelli G; Rossi FM; Niscola P; Buccisano F; Bomben R; Zucchetto A; Maurillo L; de Fabritiis P; Amadori S; Gaidano G; Gattei V; Del Poeta G
    Ann Hematol; 2014 Oct; 93(10):1765-74. PubMed ID: 24923451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
    Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].
    Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
    Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
    Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
    Bhoi S; Baliakas P; Cortese D; Mattsson M; Engvall M; Smedby KE; Juliusson G; Sutton LA; Mansouri L
    Haematologica; 2016 Feb; 101(2):e63-5. PubMed ID: 26589911
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression level of lipoprotein lipase in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.
    Xu W; Li JY; Shen QD; Wu YJ; Yu H; Fan L
    Int J Lab Hematol; 2009 Oct; 31(5):552-9. PubMed ID: 18616755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.
    Buhl AM; Jurlander J; Geisler CH; Pedersen LB; Andersen MK; Josefsson P; Petersen JH; Leffers H
    Eur J Haematol; 2006 Jun; 76(6):455-64. PubMed ID: 16529606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.
    Rossi D; Rasi S; Fabbri G; Spina V; Fangazio M; Forconi F; Marasca R; Laurenti L; Bruscaggin A; Cerri M; Monti S; Cresta S; Famà R; De Paoli L; Bulian P; Gattei V; Guarini A; Deaglio S; Capello D; Rabadan R; Pasqualucci L; Dalla-Favera R; Foà R; Gaidano G
    Blood; 2012 Jan; 119(2):521-9. PubMed ID: 22077063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia.
    Van Bockstaele F; Pede V; Janssens A; Callewaert F; Offner F; Verhasselt B; Philippé J
    Clin Chem; 2007 Feb; 53(2):204-12. PubMed ID: 17158192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.
    van't Veer MB; Brooijmans AM; Langerak AW; Verhaaf B; Goudswaard CS; Graveland WJ; van Lom K; Valk PJ
    Haematologica; 2006 Jan; 91(1):56-63. PubMed ID: 16434371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients.
    Rombout A; Stamatopoulos B; Lagneaux L; Lust S; Offner F; Naessens E; Vanderstraeten H; Verhasselt B; Philippé J
    PLoS One; 2015; 10(3):e0121526. PubMed ID: 25811490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia.
    Heintel D; Kienle D; Shehata M; Kröber A; Kroemer E; Schwarzinger I; Mitteregger D; Le T; Gleiss A; Mannhalter C; Chott A; Schwarzmeier J; Fonatsch C; Gaiger A; Döhner H; Stilgenbauer S; Jäger U;
    Leukemia; 2005 Jul; 19(7):1216-23. PubMed ID: 15858619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Value of NOTCH1 Mutations Detection among Chronic Lymphocytic Leukemia Patients.
    Aref S; El-Agder M; Salama O; Abouzeid T; Sabry M
    Asian Pac J Cancer Prev; 2020 May; 21(5):1295-1301. PubMed ID: 32458636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression.
    Bilban M; Heintel D; Scharl T; Woelfel T; Auer MM; Porpaczy E; Kainz B; Kröber A; Carey VJ; Shehata M; Zielinski C; Pickl W; Stilgenbauer S; Gaiger A; Wagner O; Jäger U;
    Leukemia; 2006 Jun; 20(6):1080-8. PubMed ID: 16617321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia.
    Oppezzo P; Vasconcelos Y; Settegrana C; Jeannel D; Vuillier F; Legarff-Tavernier M; Kimura EY; Bechet S; Dumas G; Brissard M; Merle-Béral H; Yamamoto M; Dighiero G; Davi F;
    Blood; 2005 Jul; 106(2):650-7. PubMed ID: 15802535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
    Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
    Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
    Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
    Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.